ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO848

Sotradecol Foam Sclerotherapy for Treatment of Symptomatic Cysts in ADPKD and Autosomal Dominant Polycystic Liver Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic


  • Martin, William P., St. Vincent's University Hospital, Dublin 4, Ireland
  • Neidert, Newton, Mayo Clinic, Rochester, Minnesota, United States
  • Bendel, Emily, Mayo Clinic, Rochester, Minnesota, United States
  • Edwards, Marie E., Mayo Clinic, Rochester, Minnesota, United States
  • Chebib, Fouad T., Mayo Clinic, Rochester, Minnesota, United States
  • Novotny, Paul, Mayo Clinic, Rochester, Minnesota, United States
  • Kremers, Walter K., Mayo Clinic, Rochester, Minnesota, United States
  • Torres, Vicente E., Mayo Clinic, Rochester, Minnesota, United States
  • Hogan, Marie C., Mayo Clinic, Rochester, Minnesota, United States

Patients frequently describe mass symptoms & reduced quality of life (QoL) that correlate with visible large liver/kidney cysts in ADPKD/ ADPLD. Since 1/18/2017 we have used cyst drainage followed by sotradecol foam sclerotherapy (SFS) to treat symptomatic, large (≥5 cm in diameter) cysts. Small volumes (20cc max) of sotradecol sclerosant admixed with air are injected under fluoroscopy to ablate the epithelial cyst lining. We studied its safety & impact on QoL & organ volumes.


In this single-center, single-arm, prospective observational study, ADPKD and ADPLD patients with compressive symptoms due to dominant (liver or kidney) cysts are referred for SFS with 3% sotradecol performed under local anesthesia. QoL using linear analog scale assessment tool (LASA), SF-12, the polycystic liver disease QoL tool (PLD-Q), equivalent opioid dose (mg/24hr), & organ volumes (planimetry using CT/MR) are recorded at baseline & 6 months post-SFS. Changes over time were tested using Wilcoxon tests and confirmed using repeated measures mixed models. Improvements >0.5 SD were considered clinically meaningful.


45 patients (mean age 55yr, 84% female) are enrolled: 12 (27%) with ADPKD, 31 (69%) with ADPLD, & 2 (4%) with cystic disease NOS. 31 (69%) & 14 (31%) underwent first SFS for symptomatic liver & kidney cysts, respectively. 56 SFS procedures (mean 1.24 per patient) have been performed to treat 68 cysts (mean 1.51 per patient). Total PLD-Q, overall QoL, physical well-being, bodily pain, & vitality improved at month 6 (Table). Non-significant reductions in organ volumes seen at 6 months is likely due to small numbers. Longer term follow-up to 12 months is ongoing.


SFS directed at symptomatic large cysts was well tolerated, improved QoL at 6 months, & decreased early satiety, SOB, pain & fullness. Smaller volume instillations of SFS have replaced alcohol sclerotherapy in our practice and are a safe option for directed therapy of symptomatic large cysts in ADPKD and ADPLD.

Mean (SD)
Change from Baseline to Month 6p-value (Wilcoxon)
Liver Volume (mL) (n=9)4587.8 (2136.3)-866.2 (1713.9)0.1679
Kidney Volume (mL) (n=7)2198.9 (3937.3)-663.6 (951.1)0.1144
PLD-Q (n=20)60.1 (18.3)-15.5 (19.7)0.0023
LASA Overall QoL (n=28)6.3 (2.3)1.1 (2.4)0.0258
LASA Physical Wellbeing (n=28)5.3 (2.1)1.3 (2.2)0.0053
SF-12 Vitality (n=29)44.2 (31.7)12.9 (31.8)0.0369
SF-12 Bodily Pain (n=27)53.0 (31.2)16.7 (27.7)0.0044
SF-12 General Health (n=29)48.6 (26.5)10.5 (30.6)0.0750
Equivalent Opioid Dose (mg/24h) (n=26)4.5 (12.1)-1.5 (6.1)0.2196


  • Private Foundation Support